Remove FDA Remove Pharma Remove Pharmaceutical manufacturing Remove Prescription
article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. Hedley Rees has written a book on pharma supply chains that is eye-opening and downright scary. Can patients really be confident in pharma supply chains? Why would a pharma company take risks like these? Patients should be scared.

article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. Citizen Petitions before the FDA. Senate Bill 562 (S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

10 New Solutions, Strategies, and Devices to Boost Adherence

PM360

The combined solution enables health plans and self-insured employers to realize immediate pharmacy cost savings and near-term medical cost reductions by integrating Levrx’s plan-specific and real-time prescription insights into the Adhere Platform medication optimization offerings. Pharma Manufacturer Solutions. Vincent Keunen.

article thumbnail

Diversity and inclusion in oncology clinical trials

Clarify Health

Food and Drug Administration (FDA) released guidance entitled, Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry. To advance equity in clinical research, the U.S. However, another study found that 0.1% 2] Figure 1.

article thumbnail

Everything You Need to Know About Market Access in China

PM360

Thus, this article aims to outline the healthcare system and key market access pathways that are opening in China for pharmaceutical products, including vaccines. Additionally, it will delve into the current trends and challenges that pharma companies need to consider when devising successful market access strategies for this unique market.

Marketing 105